Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 4, 2012, Pages 357-364

  Kang, Ha Yan ^a   Shin, Hyun Deok ^a   Kim, Suk Bae ^a   Song, Il Han ^a  

^a Dankook University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINESE UNIVERSITY PROGNOSTIC INDEX; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; JAPAN INTEGRATED STAGING; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; ENDEMIC DISEASES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84865959411     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.12.018     Document Type: Article

References (39)

1. Yarbro J.W., Page D.L., Fielding L.P., Partridge E.E., Murphy G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999, 86:2436-2446.
2. Compton C.C., Fielding L.P., Burgart L.J., Conley B., Cooper H.S., Hamilton S.R., et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:979-994.
3. Bostwick D.G., Grignon D.J., Hammond M.E., Amin M.B., Cohen M., Crawford D., et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:995-1000.
4. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
5. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
6. Vauthey J.N., Lauwers G.Y., Esnaola N.F., Do K.A., Belghiti J., Mirza N., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002, 20:1527-1536.
7. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:3329-3338.
8. The Cancer of the Liver Italian Program (CLIP) Investigators Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000, 31:840-845.
9. Kudo M., Chung H., Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol 2003, 38:207-215.
10. Leung T.W., Tang A.M., Zee B., Lau W.Y., Lai P.B., Leung K.L., et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769.
11. Park J.W. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004, 10:88-98.
12. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
13. Omata M., Lesmana L.A., Tateishi R., Chen P.J., Lin S.M., Yoshida H., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010, 4:439-474.
14. Befeler A.S., Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-1619.
15. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34:570-575.
16. Marrero J.A., Fontana R.J., Barrat A., Askari F., Conjeevaram H.S., Su G.L., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
17. Lee S.W., Han S.Y., Kim K.T., Baek Y.H., Koh I.Y., Kim B.H., et al. Evaluation of predictive value of Okuda, TNM. CLIP and JIS staging systems for hepatocellular carcinoma patients. Korean J Hepatol 2007, 13:196-207.
18. Cammà C., Di Marco V., Cabibbo G., Latteri F., Sandonato L., Parisi P., et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC. CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008, 28:62-75.
19. Chung H., Kudo M., Takahashi S., Hagiwara S., Sakaguchi Y., Inoue T., et al. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol 2008, 23:445-452.
20. Huo T.I., Lin H.C., Hsia C.Y., Wu J.C., Lee P.C., Chi C.W., et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 2007, 102:1920-1930.
21. Grieco A., Pompili M., Caminiti G., Miele L., Covino M., Alfei B., et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda. CLIP, and BCLC staging systems in a single Italian centre. Gut 2005, 54:411-418.
22. Cillo U., Bassanello M., Vitale A., Grigoletto F.A., Burra P., Fagiuoli S., et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. J Hepatol 2004, 40:124-131.
23. Cillo U., Vitale A., Grigoletto F., Farinati F., Brolese A., Zanus G., et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006, 44:723-731.
24. Levy I., Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002, 50:881-885. Liver Cancer Study Group of the University of Toronto.
25. Collette S., Bonnetain F., Paoletti X., Doffoel M., Bouché O., Raoul J.L., et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 2008, 19:1117-1126.
26. Chen C.H., Hu F.C., Huang G.T., Lee P.H., Tsang Y.M., Cheng A.L., et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method-analysis of 2010 Taiwanese patients. Eur J Cancer 2009, 45:1630-1639.
27. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005, 100:1764-1771.
28. Nanashima A., Sumida Y., Abo T., Shindou H., Fukuoka H., Takeshita H., et al. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol 2006, 41:250-256.
29. Kondo K., Chijiiwa K., Nagano M., Hiyoshi M., Kai M., Maehara N., et al. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma. Hepatogastroenterology 2007, 54:1534-1538.
30. Lu W., Dong J., Huang Z., Guo D., Liu Y., Shi S. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 2008, 23:1874-1878.
31. Seong J., Shim S.J., Lee I.J., Han K.H., Chon C.Y., Ahn S.H. Evaluation of the prognostic value of Okuda. Int J Radiat Oncol Biol Phys 2007, 67:1037-1042.
32. Huang Y.H., Chen C.H., Chang T.T., Chen S.C., Wang S.Y., Lee H.S., et al. Evaluation of predictive value of CLIP, Okuda. TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol 2005, 20:765-771.
33. Cho Y.K., Chung J.W., Kim J.K., Kim J.K., Ahn Y.S., Kim M.Y., et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 2008, 112:352-361.
34. Tandon P., Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009, 29:502-510.
35. Nobuoka D., Kato Y., Gotohda N., Takahashi S., Nakagohri T., Konishi M., et al. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 2010, 24:521-528.
36. Nanashima A., Taura N., Abo T., Ichikawa T., Sakamoto I., Nagayasu T., et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patients survival. Dig Dis Sci 2011, 56:3086-3100.
37. Guglielmi A., Ruzzenente A., Pachera S., Valdegamberi A., Sandri M., D'Onofrio M., et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008, 103:597-604.
38. Chen T.W., Chu C.M., Yu J.C., Chen C.J., Chan D.C., Liu Y.C., et al. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol 2007, 33:480-487.
39. Ueno S., Tanabe G., Sako K., Hiwaki T., Hokotate H., Fukukura Y., et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001, 34:529-534.